BRNS · Barinthus Biotherapeutics plc.
$0.57
-0.03 (-5.16%)
At close · Jul 28
Market Cap
$23.28M
Shares
40.85M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.57
Open$0.59
Day$0.56–0.59
52W$0.51–1.83
Avg vol 30d45K
Short int29K · 0.1% float · 1.0d
Short vol73%
Last earningsMay 7, 2025
DataApr 2021–Jul 2026
Filing10-Q · Apr 30
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Apr 30, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−23%
below
Price vs 50-day avg
−14%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
4%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−19%
trailing
6-month return
−21%
trailing
YTD return
−19%
this year
Relative strength
−29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 14 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.07% of float · ▼ -34.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
14 holders — mid 3-yr range
Squeeze score
19
low risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
−6%
Y/Y
Free cash flow
$-48.0M
Balance sheet
$70.3M
net cash
Quant / Vol
risk profile
Volatility
82%
annualized · 1-yr
Max drawdown
−70%
past year
ATR
8.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−23%
Bearish
Price vs 50-day avg
−14%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
4%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 14 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.07% of float · ▼ -34.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
14 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 4%
52-wk high $2
vs 200-day avg -23%
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BRNS
this stock
Barinthus Biotherapeutics plc.
|
$23.28M | -18.6% | -100.0% | — | 0.1% |
|
ONC
BeOne Medicines Ltd.
|
$477.60B | +7.3% | +22179.2% | 971.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BRNS | -7.6% | -18.6% | -21.4% | -13.6% | -18.6% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -6.6% | -18.6% | -28.8% | -12.9% | -27.2% |